Ahmed Ibrahim: Optimal Antithrombotic Therapy for Secondary Stroke Prevention in Patients with AF and ASCVD
Ahmed Ibrahim, Medical Student at Alexandria University, shared a post on LinkedIn about a recent article that he and his colleagues co-authored:
“For patients with ischemic stroke and comorbid Atrial Fibrillation (AF) and Atherosclerotic Cardiovascular Disease (ASCVD), does adding an antiplatelet to an anticoagulant do more harm than good in secondary stroke prevention?
Key Findings from our Network Meta-Analysis (should be interpreted with caution and contextualized within the study’s limitations):
The Power of One: OAC monotherapy emerged as the most favorable strategy for secondary prevention. It provides a balanced profile, offering strong protection against recurrent strokes with potential lower risk of major bleeding compared to combination therapy.
Less is More: Adding antiplatelet therapy (APT) to an anticoagulant did not provide additional clinical benefit. It may increase the risk of major bleeding without significantly reducing the risk of further ischemic events or death.
APT Alone: While APT monotherapy had the lowest bleeding risk, it was associated with a concerning trend toward increased all-cause mortality and was the least effective at preventing recurrent ischemic strokes.
Take-Home Message:
- In secondary stroke prevention for patients with AF and ASCVD, OAC monotherapy appears to offer a favorable balance between efficacy and safety.
- While combination therapy may be considered in select cases with compelling indications, routine use of antiplatelet therapy alongside anticoagulation should be approached with caution due to potential increased bleeding risk without clear added benefit.
Grateful to my colleagues Elsayed Balbaa, Ameer Awashra, Abdalhakim Shubietah, Giulia Cavolina, Alessio villari.
Heartfelt thanks to our seniors, Prof. Giuseppe Andò and Dr. Pierre F. Sabouret, for their invaluable support and guidance.”
Title: Optimal antithrombotic therapy for post-ischemic stroke patients with atrial fibrillation and atherosclerotic cardiovascular disease: A frequentist network meta-analysis
Authors: Ahmed Ibrahim, Elsayed Balbaa, Ameer Awashra, Abdalhakim Shubietah, Giulia Cavolina, Alessio Villari, Giuseppe Andò, Pierre Sabouret
Read Full Article on Journal of the Neurological Sciences.
Stay updated with Hemostasis Today.
-
Apr 22, 2026, 12:57Ali AlBahar: DNA Drives the Molecular Era of Blood Typing
-
Apr 22, 2026, 11:47We Are Excited to Introduce You to the 11th Editor-in-Chief Dr. Bob Löwenberg – Blood Journals Portfolio
-
Apr 22, 2026, 11:35Congratulations to Donald Arnold for Being Recognized with The ISTH 2026 Harold R. Roberts Award
-
Apr 22, 2026, 11:27Prashasti Dahiya: Key Molecular Insights on Thromboinflammation and Angiogenesis in Pediatric Cancer
-
Apr 22, 2026, 11:17Jack Hadfield: Understanding the Immune and Genetic Basis of VITT Post-COVID Vaccines
-
Apr 22, 2026, 07:56Shruti Kharat: Closing the Gap in Early Detection of Factor VIII Inhibitors
-
Apr 22, 2026, 07:46Gregory Piazza: Ushering in a New Era in PE Therapy and Improved Clinical Outcomes for Our Patients
-
Apr 22, 2026, 07:40Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
-
Apr 22, 2026, 07:36Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar 61